DexCom (NASDAQ:DXCM) Upgraded to “Strong-Buy” at Wall Street Zen

DexCom (NASDAQ:DXCM) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday.

Other equities analysts have also issued reports about the company. Morgan Stanley lifted their price objective on DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. JPMorgan Chase & Co. dropped their price target on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Friday, October 31st. Wells Fargo & Company set a $93.00 price target on shares of DexCom and gave the company an “overweight” rating in a research report on Friday, October 31st. Weiss Ratings reissued a “hold (c-)” rating on shares of DexCom in a research report on Wednesday, October 8th. Finally, Stifel Nicolaus assumed coverage on DexCom in a research report on Tuesday, October 21st. They set a “buy” rating and a $85.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.86.

DexCom Trading Down 5.2%

NASDAQ DXCM traded down $3.02 during trading hours on Friday, reaching $55.00. The company’s stock had a trading volume of 10,936,877 shares, compared to its average volume of 4,512,275. The firm has a fifty day simple moving average of $69.24 and a 200-day simple moving average of $77.57. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. DexCom has a 52 week low of $54.11 and a 52 week high of $93.25. The stock has a market cap of $21.45 billion, a P/E ratio of 38.19, a P/E/G ratio of 1.43 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.04. The firm had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.45 earnings per share. DexCom has set its FY 2025 guidance at EPS. Equities analysts forecast that DexCom will post 2.03 earnings per share for the current fiscal year.

Insider Activity

In other DexCom news, Director Kyle Malady sold 667 shares of the stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the sale, the director owned 22,667 shares in the company, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Sadie Stern sold 1,466 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the transaction, the executive vice president owned 105,223 shares in the company, valued at $8,417,840. The trade was a 1.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 5,383 shares of company stock valued at $434,274 over the last quarter. 0.32% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. King Wealth Management Group bought a new stake in shares of DexCom during the 3rd quarter worth $269,000. Marble Harbor Investment Counsel LLC grew its position in DexCom by 2.7% during the third quarter. Marble Harbor Investment Counsel LLC now owns 162,948 shares of the medical device company’s stock valued at $10,965,000 after buying an additional 4,293 shares during the period. Beirne Wealth Consulting Services LLC purchased a new position in DexCom in the third quarter valued at about $208,000. NEOS Investment Management LLC boosted its stake in DexCom by 58.7% in the third quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company’s stock valued at $11,842,000 after acquiring an additional 65,066 shares during the last quarter. Finally, Rothschild Investment LLC grew its position in shares of DexCom by 59.9% during the 3rd quarter. Rothschild Investment LLC now owns 654 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 245 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.